Financial Performance - The company's revenue for Q1 2024 was ¥60,963,422.30, a decrease of 83.63% compared to ¥372,402,234.89 in the same period last year[3] - Net profit attributable to shareholders was ¥32,052,081.48, down 57.52% from ¥75,450,691.09 year-on-year[3] - The company reported a basic earnings per share of ¥0.14, a decline of 71.43% from ¥0.49 in the same period last year[3] - Total operating revenue for Q1 2024 was CNY 60,963,422.30, a decrease of 83.7% compared to CNY 372,402,234.89 in the same period last year[16] - Net profit for Q1 2024 was CNY 28,108,162.20, a decline of 65.5% compared to CNY 81,455,808.44 in Q1 2023[17] - Earnings per share for Q1 2024 were CNY 0.14, down from CNY 0.49 in the same quarter last year[18] Cash Flow - The net cash flow from operating activities improved to ¥45,688,082.68, a significant increase of 113.39% compared to a negative cash flow of -¥341,182,026.20 in the previous year[3] - Cash inflow from operating activities was CNY 294,315,194.08, a decrease of 28.2% from CNY 410,773,725.79 in the previous year[19] - The net cash flow from operating activities for Q1 2024 was ¥45,688,082.68, a significant improvement compared to the net cash outflow of ¥341,182,026.20 in the same period last year[20] - The company reported a total cash outflow from operating activities of ¥248,627,111.40 in Q1 2024, compared to ¥751,955,751.99 in the previous year, showing improved cash management[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,240,838,105.70, a decrease of 1.97% from ¥7,386,599,894.20 at the end of the previous year[3] - The total liabilities decreased from ¥1,019,362,336.64 to ¥858,191,366.70, indicating a reduction in current liabilities[13] - The total assets of the company are ¥7,240,838,105.70, down from ¥7,386,599,894.20[13] - The total liabilities decreased to CNY 932,938,163.48 from CNY 1,094,498,430.83, indicating a reduction of 14.8%[17] Investments and Expenses - The company’s research and development expenses were ¥27,181,929.06, down 18.09% from ¥33,184,792.04 in the previous year[8] - Research and development expenses for Q1 2024 were CNY 27,181,929.06, down 18.1% from CNY 33,184,792.04 in Q1 2023[17] - The company’s investment income increased by 20.82% to ¥26,856,887.97 compared to ¥22,229,018.90 in the previous year[8] - Sales expenses decreased to CNY 24,076,564.00, a reduction of 47.6% compared to CNY 45,958,031.73 in the previous year[17] - Management expenses were CNY 18,843,544.05, down 33.1% from CNY 28,131,259.82 year-over-year[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 36,071[10] - The largest shareholder, Chen Lili, holds 27.06% of the shares, totaling 62,918,895 shares[10] - The company has no preferred shareholders as of the reporting period[11] Cash and Cash Equivalents - The cash and cash equivalents at the end of the period are ¥985,872,470.91, down from ¥1,015,682,930.54[12] - The total cash and cash equivalents at the end of Q1 2024 stood at ¥884,229,415.35, down from ¥3,196,431,442.74 at the end of Q1 2023[20] Other Financial Metrics - The company’s short-term borrowings decreased by 87.30% to ¥3,000,000.00 from ¥23,614,136.50 in the previous year[8] - The company’s cash flow from investing activities was -¥60,596,877.14, a decrease of 106.29% compared to ¥962,712,215.42 in the previous year[9] - Total cash outflow from investing activities was ¥66,088,150.65, compared to ¥1,003,522,693.89 in Q1 2023, indicating a reduction in investment expenditures[20] - The company experienced a negative impact of ¥376,414.61 from exchange rate fluctuations on cash and cash equivalents[20] Accounting and Audit - The company did not conduct an audit for the Q1 2024 report, which may affect the perception of financial reliability[22] - The company has not adopted the new accounting standards for the current year, which may impact future financial reporting[21]

公司主要产品和服务覆盖三大领域：体外诊断试剂和仪器、急危重症信息化解决方案、 第三方医学检验服务。 2023 年度总经理工作报告 尊敬的各位董事： 我谨代表公司经营管理层向董事会作 2023 年度总经理工作报告。 武汉明德生物科技股份有限公司（以下简称"公司"）主要从事体外诊断试剂和诊断仪 器的研发、生产、销售和服务，致力于成为一家为医疗机构提供创新、领先医疗服务产品的 龙头企业。公司融合创新，深耕客户需求，聚焦急危重症领域，延伸出体外诊断检测、第三 方医学检验、认证咨询服务和医疗信息化平台建设等一系列综合解决方案，支持医疗机构提 供更加即时、精准、智慧的医疗服务，从而帮助患者享受到更加便捷、优质的医疗健康服务。 历经多年发展，公司已发展成为中国领先的体外诊断综合解决方案供应商。未来，公司将继 续以"创新即时诊断，引领智慧医疗"为使命，坚持"以客户为中心，以奋斗者为本，拥抱 变化、持续学习和成长"的核心价值观，持续打造以人的医疗健康服务需求为中心的服务闭 环。 一、2023 年年度工作情况 （一）2023年公司整体经营情况 报告期内，公司实现营业收入74,953.68万元，较上年同期下降92.88%；实现利润 ...

2023 年年度非经营性资金占用及其他关联资金往来情况汇总表 法定代表人：陈莉莉 主管会计工作的负责人：王锐 会计机构负责人：黎朝辉 | 非经营性资金占用 | 资金占用 | 占用方与上市公 | 上市公司核算 | 报告期初占用 | 报告期内占用累计发生 | 报告期内占用资金 | 报告期内偿还 | 报告期末占 | 占用形成原 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 方名称 | 司的关联关系 | 的会计科目 | 资金余额 | 金额（不含利息） | 的利息（如有） | 累计发生金额 | 用资金余额 | 因 | | | 控股股东、实际控制 | | | | | | | | | | | | 人及其附属企业 | | | | | | | | | | | | 小计 | - | - | - | - | - | - | - | - | - | - | | 前控股股东、实际控 | | | | | | | | | | | | 制人及其附属企业 | | | | | | | | | | | | 小计 | - | - | ...

武汉明德生物科技股份有限公司 2023 年监事会工作报告 2023 年度，武汉明德生物科技股份有限公司（以下简称"公司"）监事会根 据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》 （以下简称"《证券法》"）、《公司章程》、《监事会议事规则》等有关规定的要求， 本着对全体股东负责的精神，认真履行和独立行使了监事会的职权，对 2023 年 度公司的经营活动、财务状况、关联交易以及高级管理人员履行职责等方面实施 了有效监督，较好地保障了公司股东权益、公司利益和员工的合法权益，促进了 公司的规范运作。 现将 2023 年度监事会主要工作报告如下： 一、监事会召开会议情况 （二）公司财务情况 报告期内，公司监事会对公司及下属各分子公司的财务状况和现行财务管理 制度定期进行了认真检查，特别对公司的会计估计和会计政策变化进行了详细的 调查。 二、监事会对公司 2023 年度有关事项的核查意见 报告期内，公司监事会根据《公司法》、《证券法》、《公司章程》、《监事会议 事规则》等有关规定，从维护公司利益和所有股东权益角度出发，认真履行监事 会的职能，对公司的依法运作、财务状况、对外投资、关联交易 ...

武汉明德生物科技股份有限公司 2023 年度募集资金存放与使用情况 专项报告的鉴证报告 信会师报字[2024]第 ZE10271 号 武汉明德生物科技股份有限公司 2023 年度募集资金存放与使用情况 专项报告的鉴证报告 | | 目 | 录 | 页 次 | | --- | --- | --- | --- | | 一、 | 鉴证报告 | | 1-2 | | 二、 | 关于公司募集资金存放与使用情况的专项报告 | | 1-7 | 关于武汉明德生物科技股份有限公司2023年度募集资金存 放与使用情况 专项报告的鉴证报告 信会师报字[2024]第ZE10271号 武汉明德生物科技股份有限公司全体股东： 我们接受委托，对后附的武汉明德生物科技股份有限公司（以下 简称"明德生物"） 2023年度募集资金存放与使用情况专项报告（以 下简称"募集资金专项报告"）执行了合理保证的鉴证业务。 一、董事会的责任 明德生物董事会的责任是按照中国证券监督管理委员会《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求 （2022年修订）》（证监会公告〔2022〕15号）、《深圳证券交易所 上市公司自律监管指引第1号——主板 ...

信会师报字[2024]第ZE10274号 武汉明德生物科技股份有限公司全体股东： 我们审计了武汉明德生物科技股份有限公司(以下简称"明德生 物")2023 年度的财务报表，包括 2023 年 12 月 31 日的合并及母公司 资产负债表、2023 年度合并及母公司利润表、合并及母公司现金流 量表、合并及母公司所有者权益变动表和相关财务报表附注，并于 2024 年 4 月 25 日出具了报告号为信会师报字[2024]第 ZE10273 号的 无保留意见审计报告。 在对上述财务报表执行审计的基础上，我们接受委托，对后附的 明德生物2023年度营业收入扣除情况表（以下简称"营业收入扣除情 况表"）执行了合理保证的鉴证业务。 一、管理层的责任 关于武汉明德生物科技股份有限公司 2023 年度营业收入扣除情况表 的鉴证报告 信会师报字[2024]第 ZE10274 号 关于武汉明德生物科技股份有限公司2023年度 营业收入扣除情况表的鉴证报告 明德生物管理层的责任是按照《深圳证券交易所股票上市规则》 的相关规定编制营业收入扣除情况表，确保营业收入扣除情况表真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 我们 ...

一、基本情况 武汉明德生物科技股份有限公司 2023 年度独立董事述职报告 （施先旺） 尊敬的各位股东及股东代表： 本人作为武汉明德生物科技股份有限公司（以下简称"公司"）的独立董事， 根据《公司法》、《上市公司治理准则》、《上市公司独立董事管理办法》等法 律法规及《公司章程》、《独立董事工作细则》等规定和要求，本着客观公正、 独立的原则，忠实、勤勉履行职责，积极出席相关会议，认真审议会议议案，充 分发挥独立董事及各专门委员会的作用，维护公司及全体股东的利益。现将 2023 年度履行独立董事职责的情况报告如下： （一）工作履历、专业背景及兼职情况 施先旺：博士研究生学历。1996 年 7 月至今任中南财经政法大学会计学院 教师，2015 年 4 月至 2021 年 5 月任武汉金运激光股份公司独立董事，2019 年 12 月至今任深圳国人科技股份公司独立董事，2022 年 3 月至今任葵花药业集团 股份有限公司独立董事。2022 年 10 月 21 日至今任公司独立董事。 （二）独立性情况说明 本人具备《上市公司独立董事管理办法》所要求的独立性，并按照监管规则 进行了独立性自查，不存在影响独立性的情况。 二、 ...

证券代码：002932 证券简称：明德生物 公告编号：2024-026 武汉明德生物科技股份有限公司 关于 2023 年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 根据中国证监会发布的《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求》和深圳证券交易所颁布的《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等有关规定，武汉明德生物科技股份有限公司（以下简 称"公司"）董事会编制了 2023 年度募集资金存放与实际使用情况的专项报告。 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 1、公司首次公开发行募集资金的到位情况 经中国证券监督管理委员会《关于核准武汉明德生物科技股份有限公司首次公开发 行股票的批复》（证监许可[2018]906 号）核准，公司首次公开发行人民币普通股（A 股） 股票 16,646,287 股，每股面值人民币 1 元，每股发行价格为人民币 20.45 元，募集资金 总额为人民币 340,416,569.15 元，扣除发行费用人民币 27,770, ...

武汉明德生物科技股份有限公司 审计报告及财务报表 二○二三年度 武汉明德生物科技股份有限公司 审计报告及财务报表 （2023 年 01 月 01 日至 2023 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-6 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-110 | 审计报告 信会师报字[2024]第 ZE10273 号 武汉明德生物科技股份有限公司全体股东： 一、 审计意见 我们审计了武汉明德生物科技股份有限公司（以下简称明德生物） 财务报表，包括 2023 年 12 月 31 日的合并及母公司资产负债表，2023 年度的合并及母公司利润表、合并及母公司现金流量表、合并及母公 司所有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则 ...

Financial Performance - The company reported a significant decline in revenue, achieving a total of 749.54 million yuan in 2023, a decrease of 92.88% compared to 10.53 billion yuan in 2022[121]. - The net profit attributable to shareholders was 74.93 million yuan, down 98.22% from the previous year[121]. - Revenue from in vitro diagnostic products and solutions was 393.38 million yuan, representing 52.48% of total revenue, a decline of 96.05% year-on-year[123]. - The company reported a significant decline in sales and production due to a sharp drop in demand for COVID-19 testing products, leading to a substantial decrease in revenue and inventory levels[134]. - The company reported a net cash decrease of ¥1,641,365,240.37, a decline of 220.22% compared to the previous year, primarily due to reduced revenue from COVID-19 products[143]. - The company’s revenue for the medical manufacturing industry was approximately ¥749.54 million, a decrease of 92.88% year-over-year, with a gross margin of 54.28%, down 12.57% from the previous year[125]. - The gross margin for third-party medical testing was 59.62%, with a revenue decrease of 29.35% year-over-year[125]. - The company anticipates a steady growth rate of approximately 15% in revenue for the upcoming fiscal year, driven by new product launches and market expansion efforts[98]. Market Trends and Competition - The company recognizes the risk of intensified market competition, particularly in the chemiluminescence sector, where imported brands hold about 70% market share[9]. - The domestic in vitro diagnostics market exceeds 100 billion yuan, with the immunodiagnostics segment, particularly chemiluminescence, holding a market share of approximately 50 billion yuan[187]. - The average price reduction for clinical testing reagents in the centralized procurement process reached 53.9%, indicating a substantial impact on pricing strategies[7]. - The average price reduction in centralized procurement for coagulation and myocardial infarction clinical testing reagents was 40.16%[7]. - The company faces risks from changes in industry policies, particularly in the in vitro diagnostics sector, which is highly correlated with healthcare policies, leading to a significant decline in demand for COVID-19 testing products[182]. Research and Development - The company plans to increase R&D investment and expand its product lines to mitigate risks associated with policy changes and market competition[5]. - The company has committed to maintaining high R&D investment to ensure core technological capabilities and product innovation[12]. - The company is focusing on expanding its product line in immunoassay testing, which is expected to drive future revenue growth[97]. - The company plans to invest in R&D for new technologies, aiming to improve the accuracy and efficiency of its diagnostic tests[104]. - The company has made significant investments in R&D, forming a team primarily composed of returning PhDs to drive product innovation[113]. Product Development and Innovation - The company focuses on three main product lines: molecular diagnostics, immunodiagnostics, and blood gas diagnostics[77]. - The immunodiagnostic product line includes high-throughput POCT technology platform QMT8000, which can detect 5 items in 15 minutes, leading the domestic market[79]. - The company has developed a comprehensive range of in vitro diagnostic products, including rapid test kits for COVID-19 and other infectious diseases[110]. - The company has launched multiple new diagnostic kits, including the D-Dimer test kit and the IL-6 test kit, with a validity period extending to 2027[103]. - The company has introduced advanced technologies in its testing processes, improving efficiency by 30% compared to previous methods[101]. Strategic Plans and Future Outlook - The company plans to continue expanding its market reach and exploring potential mergers and acquisitions to drive growth[24]. - The company aims to enhance its competitive edge by focusing on innovation, talent development, and academic research[11]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[97]. - The company has provided a positive outlook for 2024, projecting a revenue growth of 25% driven by new product launches and market expansion strategies[101]. - The company aims to increase its international sales contribution to 30% of total revenue by 2026, up from 20% currently[100]. Governance and Compliance - The company has established a strong governance structure to ensure transparency and accountability[19]. - The company emphasizes its commitment to environmental and social responsibility in its operations[20]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective corporate governance practices[197]. - Independent directors constitute more than one-third of the board, complying with legal and regulatory requirements[200]. Operational Efficiency - The company has implemented changes in accounting policies due to the new accounting standards effective from January 1, 2023[36]. - The company has established a comprehensive quality management system compliant with ISO13485 and NMPA regulations, ensuring product quality throughout the lifecycle[118]. - The company has a well-established after-sales service system that enhances customer satisfaction and brand recognition in the in vitro diagnostic field[117]. - The company has upgraded several key products to comply with IVDR standards, ensuring regulatory compliance and market readiness[110]. Market Expansion and Partnerships - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[99]. - The company has established strategic partnerships to facilitate market expansion and enhance distribution channels[98]. - The company has launched various products in 2022, including multi-center solutions and integrated critical care solutions, enhancing its service offerings[93]. - The company has established demonstration centers for its emergency information systems, gaining recognition from experts in the field[112].